All articles by Ellen Capon (Drug Target Review) – Page 2
-
ArticleInvestigating antipsychotics in a Parkinson’s disease psychosis model
In this Q&A, Dr Nicholas Waters, Head of R&D at IRLAB, shares how three compounds, including IRLABs Mesdopetam and an experimental dopamine D3 receptor antagonist, could reverse features associated with the psychosis-like state of Parkinson’s disease.
-
ArticleDeveloping an mRNA therapy for Duchenne muscular dystrophy
In this Q&A, Aki Ko, CEO and co-founder of Elixirgen Therapeutics, elucidates how their new mRNA technology could potentially restore muscle function in those suffering from Duchenne muscular dystrophy.
-
Article
The advancement of drug-free immunotherapy
Researchers have created a neutrophil therapy, involving micropatches that maintain the cells’ antitumour state, which could offer significant clinical and commercial value.
-
ArticleVitamin A and its role in psychiatric and other disorders
In this Q&A, Dr Murray Cairns, NHMRC Leadership Research Fellow at the University of Newcastle, shares his insights about the genetic influences on circulating retinol, and explains how a retinol polygenic score could be utilised in a precision medicine approach.
-
ArticleStreamlining the path from lab to market with 3D bioprinting
In this Q&A, Dr Vidmantas Šakalys, CEO of Vital3D, provides insights into the potential of 3D bioprinting to revolutionise the traditional drug development process, facilitating more accurate models and limiting the use of animal testing.
-
ArticleBile acids and the microbiome: revolutionising disease approaches
Thousands of bile acids have been discovered, providing new insights into how microbes influence distant organ systems.
-
ArticleBreakthrough for pancreatic cancer treatment
Researchers have designed the first small molecule drug targeting K-Ras GD12, which could improve pancreatic cancer outcomes.
-
ArticleScalable precision design targeting complex product profiles
We had the privilege of speaking to Dr Víctor Sebastián Pérez, Associate Director of Computational Drug Design, following his presentation at ELRIG UK 2023. He shares his insights into how Exscientia is using AI to design drug candidates for cancer treatment.
-
ArticleColon cancer: distinct transcriptional programmes identified
Researchers elucidate the significant role of CDX2 in regulating stemness and differentiation, particularly in the proximal colon’s epithelial cells. This research encourages new combinations of existing drugs, that inhibit both the BRAF and KRAS genes, to be explored.
-
ArticleMediating BRAF-mutant melanoma resistance
In this Q&A, esteemed Dr Rhoda Alani discusses the epigenetic landscape of therapy resistant melanomas and elucidates how corin treatment impacts the reprogramming of melanoma cell phenotypes. The findings suggest a new treatment paradigm for melanoma which could also be relevant to targeted therapy resistance mechanisms for other cancer types.
-
ArticleA promising new option for male contraception
Scientists have targeted the SMRT-retinoic acid receptor interaction, which could provide a reversible and non-hormonal male contraceptive method.
-
ArticleInsights into cellular therapies for cancer treatment
Many exciting developments are expected to take place in immunotherapy and oncology in the next few years. We had the privilege of discussing the opportunities of various cell therapies with Dr Suresh Nair, Physician in Chief, who elucidates how Lehigh Valley Topper Cancer Institute is directing research towards better treatments, ...
-
ArticleA new genetic biomarker to predict immunotherapy success
Tumours with a greater IGR burden could respond better to immune checkpoint blockades, advancing precise treatments for patients.
-
ArticleModelling pregestational diabetes-induced congenital heart disease
Using an advanced human heart organoid system, researchers found the contributing factors to the condition and possible therapeutic compounds.
-
ArticleInternational Day for Women and Girls in Science: Jane Kendrew
In light of the International Day for Women and Girls in Science, we had the privilege of speaking to Dr Jane Kendrew, Director of Translational Oncology at Sygnature Discovery. With over 30 years of drug discovery experience, she shares many insights, including her inspiration to pursue a career in STEM, ...
-
ArticleUnlocking the power of stem cell therapy
In this Q&A, founder of Scheer Medical Wellness Dr Alexander Scheer shares his insights, discussing the current challenges in stem cell therapy and how these can be addressed, the advancements in delivery techniques, and stem cells’ overall potential in regenerative medicine.
-
ArticleInvestigating the intratumoural microbiome in young-onset CRC patients
New insights about young-onset CRC tumour-related bacteria could lead to new diagnostic markers and therapeutic targets.
-
ArticleSARS-CoV-2 viral peptide fragments cause serious inflammatory response
In this Q&A, Dr Gerard Wong elucidates the inflammatory capacity of fragmented viral components from the perspective of supramolecular self-organisation.
-
ArticleUnderstanding how macrophages direct tissue regeneration
Distinct macrophage signatures that align specifically with regeneration could offer novel therapies to enhance wound healing.
-
ArticleHow 3D human tissue models are transforming drug discovery
In this Q&A, Keith Murphy, CEO of Organovo, discusses how the shift from animal models to 3D human tissues can transform the preclinical space. Among his many insights, he details the limitations of animal models, how Organovo’s 3D human tissue models facilitate a deeper understanding of genetic expression within specific ...
- Previous Page
- Page1
- Page2
- Page3
- Page4
- Next Page